FDA Clears Atrium's IND for ATR 1072, Phase 1/2 Trial to Start
RNA is trading near its 52-week low of $11.403 (7.2% above the low).
Summary
Atrium Therapeutics received FDA clearance for its IND application for ATR 1072, a gene therapy candidate for PRKAG2 syndrome. The clearance allows the company to initiate the Corventis Phase 1/2 trial, an open-label, multicenter study enrolling approximately 37 participants. Part A will evaluate safety and dose selection, while Part B is a single-arm expansion at the recommended dose. Site initiation is underway, with the first participant expected by end of 2026 and initial proof-of-concept data anticipated in H2 2027. This marks a significant step for the recently spun-off company, which reported a strong $267.8 million cash balance in Q1 2026, providing a solid runway to advance its pipeline. The news follows the 8-K filed earlier today, adding trial design and timeline specifics that were not previously disclosed.
At the time of this announcement, RNA was trading at $12.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $209M. The 52-week trading range was $11.40 to $16.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.